The Safety, Tolerability and Preliminary Efficacy of NouvNeu001 for Early-onset Parkinson's Disease

This trial is testing an experimental cell therapy called NouvNeu001 for people with early-onset Parkinson's disease — meaning Parkinson's that started at age 50 or younger. The treatment involves transplanting specially prepared cells into the brain to try to replace the nerve cells that are lost in Parkinson's disease. This is an early-phase trial focused on safety and initial effectiveness. **You may be eligible if...** - You are between 18 and 70 years old - You were diagnosed with Parkinson's disease and your symptoms first appeared at age 50 or younger - Your Parkinson's symptoms are moderate to severe when your medication has worn off - You responded positively to a levodopa medication test - You are medically fit for brain surgery under anesthesia **You may NOT be eligible if...** - You have atypical Parkinsonism (other conditions that mimic Parkinson's) - You have previously had brain surgery for Parkinson's (e.g., pallidotomy, deep brain stimulation) - Your lab tests fall outside acceptable ranges Talk to your doctor to see if this trial is right for you.